公开(公告)号：US20030190323A1

公开(公告)日：2003-10-09

申请号：US10307326

申请日：2002-12-02

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Irun R. Cohen ,  Dana Elias ,  Meir Shinitzky

IPC: A61K039/00 ,  A61K035/78

CPC classification number: A61K38/1709 ,  A61K9/0029 ,  A61K39/0008 ,  A61K39/39 ,  A61K2039/55566 ,  A61K2039/57 ,  C07K14/4713 ,  C07K16/18

Abstract: The present invention provides pharmaceutical compositions and methods for reducing the incidence or severity of insulin dependent diabetes mellitus, insulitis, null-cell destruction, or latent autoimmune diabetes in adults by administering to a patient a pharmaceutical composition comprising an antigen and a carrier, wherein the antigen is recognized by inflammatory T cells associated with the pathogenesis of the disease and the carrier is a metabolizable lipid emulsion. The composition induces a TH1nullTH2 shift in the cytokines produced by said T cells and it is administered in an amount, which is therapeutically effective to reduce the symptoms of the disease.

Abstract translation: 本发明提供了通过向患者施用包含抗原和载体的药物组合物来降低成人胰岛素依赖性糖尿病，胰岛炎，β-细胞破坏或潜伏性自身免疫性糖尿病的发病率或严重程度的药物组合物和方法，其中 抗原被与疾病发病相关的炎性T细胞识别，载体是可代谢的脂质乳剂。 所述组合物诱导由所述T细胞产生的细胞因子中的TH1-> TH2位移，并且其用量以治疗方式有效减少疾病症状。